true tear FDA Approved Dry Eye Disease Device

By Staff May 16, 2017

Bowden Eye’s Premier Physicians are first to offer the newest FDA approved Dry Eye Disease Device to it’s patients

In March, Dr. Frank Bowden, Dr. Sarah Darbandi, and Dr. Jerry Robben were hand selected as premier physicians from around the country to participate in a launch study of True Tear. With no other physicians in Jacksonville selected, and only two practices in the state of Florida; Bowden Eye & Associates is excited to exclusively launch this product to our patients.

TrueTear is the latest in cutting edge technology for the treatment and management of Dry Eye Disease.  It is a treatment that is unlike any other to date. Until now, eyecare physicians have been limited to using supportive treatments,

supplements, drugs and/or procedures to help manage Dry Eye Disease. TrueTear uses a totally new treatment strategy called Neurostimulation to address Dry Eye Disease. The device was just FDA approved in April, 2017 and, because of our leadership in the treatment of Dry Eye Disease, the physicians at Bowden Eye & Associates have been chosen to be the very first doctors to prescribe it.

The neurostimulation approach with TrueTear is a proven technology that is used in well know devices like pacemakers, cochlear implants and TENS Devices for chronic back pain. TrueTear is the first and only neurostimulation device for the treatment of Dry Eye Disease and is FDA approved to safely stimulate the nerves that supply the Lacrimal Function Unit (LFU); which is the part of your eyes that supplies the natural, healthy tears that keeps our eyes moist, comfortable and clear.  The LFU is very complex, with multiple components and parts that can become damaged and breakdown in the Dry Eye Disease cycle. Past Dry Eye treatments usually focus on helping one or a few of the damaged parts only, but TrueTear has the ability to help the entire LFU naturally. It does this in a drug free way that basically turns your eyes natural tear system back on.

At this time, it is unsure if TrueTear will replace some previous treatments, but it is certain that TrueTear will enhance the effects of all Dry Eye Disease treatments and may improve patients who have reached a plateau or a block in their current treatments.  Because TrueTear is so new, and because of its revolutionary approach, the availability to physicians is limited at first.  Bowden Eye & Associates is the first practice in the country to purchase the products for our patients. These devices will be available at our Launch on May 22nd.  If you are interested, please call our office at (904) 296-0098 to schedule your May 22nd appointment.